BlackRock Inc. Takes $3.78 Million Position in Humacyte, Inc. $HUMA

Key Points

• BlackRock acquired 4.84 million Humacyte shares worth approximately $3.78 million, giving it a 2.18% stake. Institutional investors and hedge funds collectively own 44.71% of the company.
• Analyst sentiment is generally positive but mixed, with six Buy ratings and one Sell rating. Humacyte has an overall “Moderate Buy” rating and an average price target of $6.54.
• Humacyte shares opened at $0.60, near their 12-month low of $0.53, after the company reported a quarterly loss of $0.16 per share and revenue of $0.41 million, both below analyst expectations.

BlackRock Inc. purchased a new position in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 4,839,929 shares of the company's stock, valued at approximately $3,777,000. BlackRock Inc. owned approximately 2.18% of Humacyte at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Prudential Financial Inc. acquired a new stake in Humacyte in the second quarter valued at $28,000. Price T Rowe Associates Inc. MD raised its stake in shares of Humacyte by 21.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company's stock worth $73,000 after buying an additional 13,175 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Humacyte by 41.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 45,960 shares of the company's stock worth $96,000 after buying an additional 13,407 shares during the last quarter. Financial Advisors Network Inc. purchased a new stake in shares of Humacyte in the 2nd quarter worth about $28,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Humacyte by 25.5% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 76,975 shares of the company's stock worth $161,000 after buying an additional 15,649 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on HUMA shares. HC Wainwright raised their target price on shares of Humacyte from $3.00 to $4.00 and gave the company a "buy" rating in a report on Thursday, June 11th. BTIG Research reaffirmed a "buy" rating and issued a $2.00 price target on shares of Humacyte in a report on Wednesday, August 12th. Benchmark lowered their price target on shares of Humacyte from $2.00 to $1.00 and set a "speculative buy" rating on the stock in a research report on Thursday, August 13th. Weiss Ratings reissued a "sell (e+)" rating on shares of Humacyte in a research note on Wednesday, July 8th. Finally, TD Cowen dropped their price objective on shares of Humacyte from $1.50 to $1.25 and set a "buy" rating for the company in a research note on Wednesday, June 17th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Humacyte presently has an average rating of "Moderate Buy" and an average price target of $6.54.

Humacyte Price Performance

NASDAQ:HUMA opened at $0.60 on Friday. The firm has a market cap of $168.04 million, a price-to-earnings ratio of -1.23 and a beta of 2.45. The company has a current ratio of 6.21, a quick ratio of 5.74 and a debt-to-equity ratio of 2.07. The company's 50-day moving average is $0.67 and its two-hundred day moving average is $0.86. Humacyte, Inc. has a 12-month low of $0.53 and a 12-month high of $2.55.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.05). The firm had revenue of $0.41 million for the quarter, compared to analysts' expectations of $1.04 million. Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%. Research analysts expect that Humacyte, Inc. will post -0.4 EPS for the current year.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source